Health & Biotech

Health Kick Podcast: Investing in repurposed drugs, combating intracranial pressure and why Invex caught NASA’s eye

December 4, 2019December 4, 2019 | Tim Boreham

Health & Biotech

Tim Boreham: Visioneering is flexing its muscles as it vies for a share of the $US2bn kids contact lens market

December 1, 2019December 3, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: What’s holding back better breast cancer detection? And how is Volpara’s tech changing the game?

November 27, 2019December 4, 2019 | Tim Boreham

Health & Biotech

Tim Boreham: Can Phylogica finally make magic happen after nearly 15 years of trying?

November 24, 2019November 24, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: Developing drugs, fighting fibrosis and squeezing squishometers

November 20, 2019November 20, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Uscom gets an A+ for everything but its share price

November 17, 2019November 17, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: How Aussie health stocks are performing internationally and Prescient’s cancer-blocking innovation

November 13, 2019November 13, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Genetic Signatures lures the deep-pocketed backers in the battle of the bugs

November 10, 2019November 15, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: The growth of musculoskeletal disorders, new markets created by ageing populations and OCC’s Avatar moment

November 6, 2019November 6, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: PainChek on a painless path to success; shares up over 1000 per cent

November 3, 2019November 3, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: The future of X-ray, a new way to image the body and challenging clinical practice

October 30, 2019October 30, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Elixinol says FDA hemp call an ‘inflexion point’ for industry

October 27, 2019October 27, 2019 | Tim Boreham